Mizuho on Terns Pharmaceuticals (TERN): current MRK deal represents 'excellent outcome' for TERN shareholders
Mizuho analyst Graig Suvannavejh reiterated a Neutral rating and $53.00 price target on Terns Pharmaceuticals (NASDAQ: TERN)The analyst commented, "Yesterday ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)